{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rofo F"],"funding":["Torsten S??derbergs Stiftelse","Hj??rnfonden","Jeanssons Stiftelser","Olle Engqvist stiftelse","Magnus Bergvalls Stiftelse","??hl??n-stiftelsen","Stiftelsen f??r??Strategisk Forskning","Petrus och Augusta Hedlunds Stiftelse","Science for Life Laboratory","??ke Wibergs stiftelse","Vetenskapsr??det","Alzheimerfonden","VINNOVA"],"pagination":["2529-2541"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8291608"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(13)"],"pubmed_abstract":["Alzheimer's disease is the most common neurodegenerative disorder characterized by the pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in Alzheimer's disease is to enhance Aβ degradation by increasing the activity of Aβ-degrading enzymes, including neprilysin. The somatostatin (SST) peptide has been identified as an activator of neprilysin. Recently, we demonstrated the ability of a brain-penetrating SST peptide (SST-scFv8D3) to increase neprilysin activity and membrane-bound Aβ42 degradation in the hippocampus of mice overexpressing the Aβ-precursor protein with the Swedish mutation (APPswe). Using LC-MS, we further evaluated the anti-Alzheimer's disease effects of SST-scFv8D3. Following a triple intravenous injection of SST-scFv8D3, the LC-MS anal"],"journal":["ACS chemical neuroscience"],"pubmed_title":["Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide."],"pmcid":["PMC8291608"],"funding_grant_id":["FO2018-0292","2019-01885","RIF14-0078","2018-03988","2017-02413","2018???05501","ICA16-0010","2018???03320"],"pubmed_authors":["Chourlia A","Hultqvist G","Rofo F","Syvanen S","Andren PE","Jansson ET","Metzendorf NG","Sandbaumhuter FA","Morrison JI"],"additional_accession":[]},"is_claimable":false,"name":"Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.","description":"Alzheimer's disease is the most common neurodegenerative disorder characterized by the pathological aggregation of amyloid-β (Aβ) peptide. A potential therapeutic intervention in Alzheimer's disease is to enhance Aβ degradation by increasing the activity of Aβ-degrading enzymes, including neprilysin. The somatostatin (SST) peptide has been identified as an activator of neprilysin. Recently, we demonstrated the ability of a brain-penetrating SST peptide (SST-scFv8D3) to increase neprilysin activity and membrane-bound Aβ42 degradation in the hippocampus of mice overexpressing the Aβ-precursor protein with the Swedish mutation (APPswe). Using LC-MS, we further evaluated the anti-Alzheimer's disease effects of SST-scFv8D3. Following a triple intravenous injection of SST-scFv8D3, the LC-MS anal","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-21T22:34:04.957Z","creation":"2022-02-10T21:33:58.382Z"},"accession":"S-EPMC8291608","cross_references":{"pubmed":["34170117"],"doi":["10.1021/acschemneuro.1c00303"]}}